Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)
Liquidia amends exclusive license to include key markets in Europe, Japan and elsewhereLiquidia also obtains rights to Pharmosa’s next-generation nebulizers for use with L606Pharmosa to receive $3.5 million upfront and up to $157.75 million in… Read More »Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)